

Impact of Hepatitis C Virus (HCV) Screening in an Emergency Department (ED): implementation of the FOCUS program in Almería, Spain.

Anny Camelo,¹ Teresa Jordán,¹ Antonio Duarte,¹ Manuel Rodríguez,¹ Teresa Cabezas,¹
Alba Carrodegas,² Diogo Medina,² Marta Casado¹

¹ Torrecárdenas University Hospital, Almería, Spain. ² Gilead Sciences Spain & Portugal

Background

Background

World Health Organization (2015)

World Health Organization (2015)

**Global Health Sector Strategy to
eliminate viral hepatitis¹**



World Health Organization (2015)

Global Health Sector Strategy to eliminate viral hepatitis¹



The main goals of this initiative are a **90%** reduction new hepatitis infections, and a **65%** reduction in associated mortality by **2030**.

1. Global health sector strategy on viral hepatitis 2016–2021. Geneva, World Health Organization; 2016.

2. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.

World Health Organization (2015)

Global Health Sector Strategy to eliminate viral hepatitis¹



The main goals of this initiative are a **90%** reduction new hepatitis infections, and a **65%** reduction in associated mortality by **2030**.

Hepatitis C Virus in Spain

1. Global health sector strategy on viral hepatitis 2016–2021. Geneva, World Health Organization; 2016.

2. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.

World Health Organization (2015)

Global Health Sector Strategy to eliminate viral hepatitis¹



The main goals of this initiative are a **90%** reduction new hepatitis infections, and a **65%** reduction in associated mortality by **2030**.

Hepatitis C Virus in Spain

Ministry of Health serosurvey estimated (2017-2018)²:

World Health Organization (2015)

Global Health Sector Strategy to eliminate viral hepatitis¹



The main goals of this initiative are a **90%** reduction new hepatitis infections, and a **65%** reduction in associated mortality by **2030**.

Hepatitis C Virus in Spain

Ministry of Health serosurvey estimated (2017-2018)²:

- prevalence positive HCV antibodies: **0.85%**
- prevalence active infection (RNA-positive): **0.22%**

1. Global health sector strategy on viral hepatitis 2016–2021. Geneva, World Health Organization; 2016.

2. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.

World Health Organization (2015)

Global Health Sector Strategy to eliminate viral hepatitis¹



The main goals of this initiative are a **90%** reduction new hepatitis infections, and a **65%** reduction in associated mortality by **2030**.

Hepatitis C Virus in Spain

Ministry of Health serosurvey estimated (2017-2018)²:

- prevalence positive HCV antibodies: **0.85%**
 - prevalence active infection (RNA-positive): **0.22%**
- ↳ *29% viraemic patients unaware of their infection*

1. Global health sector strategy on viral hepatitis 2016–2021. Geneva, World Health Organization; 2016.

2. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.

World Health Organization (2015)

Global Health Sector Strategy to eliminate viral hepatitis¹




The main goals of this initiative are a **90%** reduction new hepatitis infections, and a **65%** reduction in associated mortality by **2030**.

Hepatitis C Virus in Spain

Ministry of Health serosurvey estimated (2017-2018)²:

- prevalence positive HCV antibodies: **0.85%**
 - prevalence active infection (RNA-positive): **0.22%**
- ↳ 29% *viraemic patients unaware of their infection*

**TO ACHIEVE
WHO'S GOALS**



1. Global health sector strategy on viral hepatitis 2016–2021. Geneva, World Health Organization; 2016.

2. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.

World Health Organization (2015)

Global Health Sector Strategy to eliminate viral hepatitis¹



The main goals of this initiative are a **90%** reduction new hepatitis infections, and a **65%** reduction in associated mortality by **2030**.

Hepatitis C Virus in Spain

Ministry of Health serosurvey estimated (2017-2018)²:

- prevalence positive HCV antibodies: **0.85%**
- prevalence active infection (RNA-positive): **0.22%**
↳ *29% viraemic patients unaware of their infection*

**TO ACHIEVE
WHO'S GOALS**



**Increasing HCV
screening is key**

1. Global health sector strategy on viral hepatitis 2016–2021. Geneva, World Health Organization; 2016.

2. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.

Background

The Emergency Department (ED): An Opportunity for Screening

The Emergency Department (ED): An Opportunity for Screening



EDs provide care to vulnerable groups:

- Socially excluded
- Migrant population
- Psychiatric disease
- Elderly population

The Emergency Department (ED): An Opportunity for Screening



EDs provide care to vulnerable groups:

- Socially excluded
- Migrant population
- Psychiatric disease
- Elderly population

Torrecárdenas University Hospital (HUT) is the main provider of care for a population of 8 municipalities in the province of Almería (**population 724,000**), in eastern Andalusia, Spain

The Emergency Department (ED): An Opportunity for Screening



EDs provide care to vulnerable groups:

- Socially excluded
- Migrant population
- Psychiatric disease
- Elderly population

Torrecárdenas University Hospital (HUT) is the main provider of care for a population of 8 municipalities in the province of Almería (**population 724,000**), in eastern Andalusia, Spain



The Emergency Department (ED): An Opportunity for Screening



EDs provide care to vulnerable groups:

- Socially excluded
- Migrant population
- Psychiatric disease
- Elderly population

Torrecárdenas University Hospital (HUT) is the main provider of care for a population of 8 municipalities in the province of Almería (**population 724,000**), in eastern Andalusia, Spain



Hospital
Torrecárdenas



The Emergency Department (ED): An Opportunity for Screening



EDs provide care to vulnerable groups:

- Socially excluded
- Migrant population
- Psychiatric disease
- Elderly population

Torrecárdenas University Hospital (HUT) is the main provider of care for a population of 8 municipalities in the province of Almería (**population 724,000**), in eastern Andalusia, Spain



Hospital
Torrecárdenas



The Emergency Department (ED): An Opportunity for Screening



EDs provide care to vulnerable groups:

- Socially excluded
- Migrant population
- Psychiatric disease
- Elderly population

Torrecárdenas University Hospital (HUT) is the main provider of care for a population of 8 municipalities in the province of Almería (**population 724,000**), in eastern Andalusia, Spain




Hospital
Torrecárdenas




HUT's ED handles

159,000 patients visits per year












Public Health initiative to promote the testing and diagnosis of Blood-Borne Virus (BBV) infections
And increase their screening and linkage to care (LTC)







METHODS

Study population:

- Adult patients **aged 18-69 y.o.**
- Who visited the **Emergency Department** for acute illness
- **Needing bloodwork** for any purpose
- **With oral consent**

METHODS

Study population:

- Adult patients **aged 18-69 y.o.**
- Who visited the **Emergency Department** for acute illness
- **Needing bloodwork** for any purpose
- **With oral consent**

Study period:

Aug. 2021 to Sep. 2023 **(25 months)**

Study population:

- Adult patients **aged 18-69 y.o.**
- Who visited the **Emergency Department** for acute illness
- **Needing bloodwork** for any purpose
- **With oral consent**

Study period:

Aug. 2021 to Sep. 2023 **(25 months)**

1. One-step strategy

**HCV antibodies
detection (anti-HCV)**
•(LIAISON®X- Diasorin)


METHODS

Study population:

- Adult patients **aged 18-69 y.o.**
- Who visited the **Emergency Department** for acute illness
- **Needing bloodwork** for any purpose
- **With oral consent**

Study period:

Aug. 2021 to Sep. 2023 **(25 months)**




Study population:

- Adult patients **aged 18-69 y.o.**
- Who visited the **Emergency Department** for acute illness
- **Needing bloodwork** for any purpose
- **With oral consent**

Study period:

Aug. 2021 to Sep. 2023 (**25 months**)




METHODS

Study population:

- Adult patients **aged 18-69 y.o.**
- Who visited the **Emergency Department** for acute illness
- **Needing bloodwork** for any purpose
- **With oral consent**

Study period:

Aug. 2021 to Sep. 2023 (**25 months**)




METHODS

Study population:

- Adult patients **aged 18-69 y.o.**
- Who visited the **Emergency Department** for acute illness
- **Needing bloodwork** for any purpose
- **With oral consent**

Study period:

Aug. 2021 to Sep. 2023 (**25 months**)



SUMMARY OF RESULTS

SUMMARY OF RESULTS

HCV Screening: **16295** patients

SUMMARY OF RESULTS

HCV Screening: 16295 patients

anti-HCV Positive (266 patients)

- Average age: 56 years / 76% male

SUMMARY OF RESULTS

HCV Screening: 16295 patients

anti-HCV Positive (266 patients)

- Average age: 56 years / 76% male

HCV RNA-Positive (60 patients)

- 80% males

SUMMARY OF RESULTS

HCV Screening: 16295 patients

anti-HCV Positive (266 patients)

- Average age: 56 years / 76% male


HCV RNA-Positive (60 patients)

- 80% males

PREVALENCE HCV

Anti-HCV: 1.63%

RNA-Positive: 0.37 %



SUMMARY OF RESULTS

HCV Screening: 16295 patients

anti-HCV Positive (266 patients)

- Average age: 56 years / 76% male

HCV RNA-Positive (60 patients)

- 80% males


PREVALENCE HCV

Anti-HCV: 1.63%

RNA-Positive: 0.37 %



AGE DISTRIBUTION (RNA +)



SUMMARY OF RESULTS

SUMMARY OF RESULTS

We identified risk factors in **50%** of viremic patients' records.
The following risk factors were the top:

SUMMARY OF RESULTS

We identified risk factors in **50%** of viremic patients' records.
The following risk factors were the top:

Injected or inhaled drug use	44%
Origin from countries with medium or high HCV prevalence	9 %
History of incarceration	8 %
HIV or HBV coinfection	2 %

SUMMARY OF RESULTS

We identified risk factors in **50%** of viremic patients' records.
The following risk factors were the top:

Injected or inhaled drug use	44%
Origin from countries with medium or high HCV prevalence	9 %
History of incarceration	8 %
HIV or HBV coinfection	2 %

MISSED OPPORTUNITIES FOR DIAGNOSING HCV INFECTION


- Prior visits Emergency Department: **76%**
- Prior visits Primary Care: **88%**



SUMMARY OF RESULTS

We identified risk factors in **50%** of viremic patients' records.
The following risk factors were the top:

Injected or inhaled drug use	44%
Origin from countries with medium or high HCV prevalence	9 %
History of incarceration	8 %
HIV or HBV coinfection	2 %



CONCLUSIONS

1

CONCLUSIONS

- ❖ Undocumented HCV infection among our population is almost twice (0.37 vs 0.22 RNA-positive) that estimated in the Spanish population.

CONCLUSIONS

- ❖ Undocumented HCV infection among our population is almost twice (0.37 vs 0.22 RNA-positive) that estimated in the Spanish population.
- ❖ HCV Screening is an effective strategy in population that only uses the Emergency Departments (EDs).

CONCLUSIONS

- ❖ Undocumented HCV infection among our population is almost twice (0.37 vs 0.22 RNA-positive) that estimated in the Spanish population.
- ❖ HCV Screening is an effective strategy in population that only uses the Emergency Departments (EDs).
- ❖ Thus, opportunistic HCV Screening in EDs is feasible, non-disruptive, effective and is necessary as a tool for Hepatitis C elimination in all Hospitals.

CONCLUSIONS

- ❖ Undocumented HCV infection among our population is almost twice (0,37 vs 0,22 RNA-positive) that estimated in the Spanish population.
- ❖ HCV Screening is an effective strategy in population that only uses the Emergency Departments (EDs).
- ❖ Thus, opportunistic HCV Screening in EDs is feasible, non-disruptive, effective and is necessary as a tool for Hepatitis C elimination in all Hospitals.

NEXT STEPS

CONCLUSIONS

- ❖ Undocumented HCV infection among our population is almost twice (0.37 vs 0.22 RNA-positive) that estimated in the Spanish population.
- ❖ HCV Screening is an effective strategy in population that only uses the Emergency Departments (EDs).
- ❖ Thus, opportunistic HCV Screening in EDs is feasible, non-disruptive, effective and is necessary as a tool for Hepatitis C elimination in all Hospitals.

NEXT STEPS

- ❖ A cost-effectiveness analysis will be made with the results of these two years to demonstrate that it is a cost-effective screening strategy.

CONCLUSIONS

- ❖ Undocumented HCV infection among our population is almost twice (0.37 vs 0.22 RNA-positive) that estimated in the Spanish population.
- ❖ HCV Screening is an effective strategy in population that only uses the Emergency Departments (EDs).
- ❖ Thus, opportunistic HCV Screening in EDs is feasible, non-disruptive, effective and is necessary as a tool for Hepatitis C elimination in all Hospitals.

NEXT STEPS

- ❖ A cost-effectiveness analysis will be made with the results of these two years to demonstrate that it is a cost-effective screening strategy.
- ❖ Hepatitis B, Hepatitis delta and HIV screening and linkage to care will be integrated into the circuit of our FOCUS HUT programme.

CONCLUSIONS

- ❖ Undocumented HCV infection among our population is almost twice (0.37 vs 0.22 RNA-positive) that estimated in the Spanish population.
- ❖ HCV Screening is an effective strategy in population that only uses the Emergency Departments (EDs).
- ❖ Thus, opportunistic HCV Screening in EDs is feasible, non-disruptive, effective and is necessary as a tool for Hepatitis C elimination in all Hospitals.

NEXT STEPS

- ❖ A cost-effectiveness analysis will be made with the results of these two years to demonstrate that it is a cost-effective screening strategy.
- ❖ Hepatitis B, Hepatitis delta and HIV screening and linkage to care will be integrated into the circuit of our FOCUS HUT programme.

ACKNOWLEDGEMENTS

Gilead Sciences' FOCUS Program funding supports screening & linkage to a first appointment after diagnosis regardless of how organizations handle subsequent patient care and treatment.